Patient satisfaction and acceptability of long-term treatment with quetiapine

International Journal of Psychiatry in Clinical Practice

Volumn 3, Issue 2, 1999, Pages 105-113

  Hellewell, J S E ^a   Kalali, A H ^b   Langham, S J ^c   Mckellar, J ^c   Awad, A G ^d  

^a TRAFFORD GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acceptability; Long term treatment; Patient satisfaction; Quetiapine; Subjective tolerability

Indexed keywords

QUETIAPINE;

ADULT; AGRANULOCYTOSIS; ARTICLE; DAILY LIFE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERCEPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 0032818246     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509909024770     Document Type: Article

References (31)

1. Naber D (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10 (suppl 3): 133-8.
2. Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67-72.
3. Falloon I, Watt DC, Shepherd M (1978) A comparative controlled trial of pimozide and fluphenasine decanoate in the continuation therapy of schizophrenia. Psychol Med 8: 59-70.
4. Hogan TP, Awad AG, Eastwood R (1983) A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13: 177-83.
5. Nelson A (1975) Drug default among schizophrenic patients. Am J Hosp Pharm 32: 1237-42.
6. Buchanan A (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22: 787-97.
7. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ (1995) Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 10 (suppl 3): 123-32.
8. Tarsey D (1983) Neuroleptic-induced extrapyramidal reactions: classification, description and diagnosis. Clin Neuropharmacol 6 (suppl 1): S9-S26.
9. Baldessarini RJ, Cole JO, Davis JM (1980) Tardive dyskinesia: a summary of a task force report of the American Psychiatric Association. Am J Psychiatry 137: 1163-72.
10. Kerwin R, Taylor D (1996) New antipsychotics: a review of their current status and clinical potential. CNS Drugs 6: 71-82.
11. Meltzer HY (1996) Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 168 (suppl 29): 23-31.
12. Saller CF, Salama AL (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacol 112: 285-92.
13. Peuskens J, Link CGG (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96: 265-73.
14. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group (1997) Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-46.
15. Small JG, Hirsch SR, Arvanitis LA et al (1997) Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54: 549-57.
16. Meats P (1997) Quetiapine ('Seroquel'): an effective and well-tolerated atypical antipsychotic. Int J Psych Clin Pract 1: 231-9.
17. Hamner MB, Arvanitis LA, Miller BG (1996) Plasma prolactin in schizophrenia patients treated with Seroquel (ICI 204,636). Psychopharmacol Bull 32: 107-110.
18. Kalali A (1999) Patient satisfaction with, and acceptability of, atypical antipsychotics. Curr Med Res Opin 15: 135-7.
19. Hogan TP, Awad AG (1992) Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 22: 347-52.
20. Awad AG (1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19: 609-18.
21. Weiden PJ, Shaw E, Mann JJ (1986) Causes of neuroleptic noncompliance. Psychiatry Ann 16: 571-5.
22. Awad AG, Hogan TP (1994) Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 89 (suppl 380): 27-32.
23. Van Putten T, May PR, Marder SR, Wittmann LA (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187-90.
24. Kalman TP (1983) An overview of patient satisfaction with psychiatric treatment. Hosp Commun Psychiatry 34: 48-54.
25. Awad AG (1995) Quality of life issues in medicated schizophrenics: therapeutic and research implications. In Contemporary issues in the treatment of schizophrenia (eds C Shriqui, H Nasrallah) 735-47. American Psychiatric Press, Washington, DC.
26. Fleming K, Kalali A, Yeh C et al (1996) Neurocognitive effects of 'Seroquel' (ICI 204,636). World Congress of Psychiatry 2: 305.
27. Williams B (1994) Patient satisfaction: a valid concept? Soc Sci Med 38: 509-16.
28. Williams B, Wilkinson G (1995) Patient satisfaction in mental health care. Evaluating an evaluative method. Br J Psychiatry 166: 559-62.
29. Keks NA (1997) Impact of newer antipsychotics on outcomes in schizophrenia. Clin Therapeut 19: 148-52.
30. Awad AG, Voruganti LNP (in press) Neuroleptics and quality of life in schizophrenia. In Quality of life and mental health care (ed S Priebe). Wrightson Biomedical Publishing, London, UK.
31. Franz M, Lis S, Plüddemann K, Galhofer B (1997) Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 170: 422-5.